Rocket Pharmaceuticals, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Gaurav D. Shah
- Full Time Employees
- 202
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 9 Cedarbrook Drive Cranbury NJ United States of America 08512
- IPO Date
- Feb 18, 2015
- CIK
- 0001281895
- Website
- rocketpharma.com
- Similar Companies
- Business
- Rocket Pharmaceuticals, Inc. (RCKT) is a fully integrated, late-stage biotechnology company that develops gene therapies for rare and devastating pediatric diseases, employing lentiviral vector (LVV) and adeno-associated viral (AAV) platforms to target genetic disorders in hematopoietic stem cells, heart, liver, and other tissues. The company's pipeline includes late-stage LVV programs for KRESLADI (RP-L201) in severe leukocyte adhesion deficiency-I (LAD-I), Fanconi anemia (FA), and pyruvate kinase deficiency (PKD); and AAV programs for Danon disease (RP-A501), plakophilin-2 arrhythmogenic cardiomyopathy (PKP2-ACM, RP-A601), and BAG3 dilated cardiomyopathy (BAG3-DCM). It operates primarily in the United States, with research, development, and manufacturing facilities in Cranbury, New Jersey, where it was founded in 2015. In July 2025, Rocket announced a strategic corporate reorganization to prioritize its AAV cardiovascular platform, including Danon disease, PKP2-ACM, and BAG3-DCM, alongside regulatory efforts for KRESLADI following FDA acceptance of its BLA resubmission in October 2025; this refocuses resources on late-stage assets after a strategy outlined in January 2025. The company targets patient populations with high unmet needs in inherited cardiomyopathies and hematologic disorders, affecting over 100,000 patients in the U.S. and EU, and maintains partnerships with institutions like the University of California and Temple University to advance its therapies.
Company News
Rocket Pharmaceuticals to Participate in Chardan's 10th Annual Healthcare Conference
Rocket Pharmaceuticals shares rise 4% after securing access to $150 million credit facility
Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar
Rocket Pharmaceuticals (NASDAQ:RCKT) Given “Buy” Rating at Chardan Capital
Rocket Pharmaceuticals Details RP-A501 Pivotal Plan After Safety Reset
Rocket Pharmaceuticals, Inc. (RCKT) Discusses Danon Disease Program Update With Focus on RP-A501 Pivotal Trial and Preliminary Clinical Data Transcript
Rocket Pharmaceuticals Details RP-A501 Pivotal Plan After Safety Reset
Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital
RCKT Aligns With FDA on Completing Phase II Study in Danon Disease
Here Are Wednesday’s Top Wall Street Analyst Research Calls: Airbnb, Booking Holdings, Credicorp, Dutch Bros, Expedia, Hartford Financial Services, Group, Meritage Homes, Patchex, Yum! Brands, and More
Rocket Pharmaceuticals, Inc. (RCKT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Rocket Pharmaceuticals, Inc. (RCKT) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease
Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease
Rocket Pharmaceuticals (RCKT) Up 6% Since Last Earnings Report: Can It Continue?
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Given Average Recommendation of “Hold” by Analysts
Rocket Pharmaceuticals Q2 Earnings Rise Y/Y, Kresladi Launch in Focus
Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress
Rocket Pharmaceuticals Touts Positive Early Safety Data from Revised Genetic Therapy Trial